The Pediatric infectious disease journal · 2026
SARS-CoV-2 Coinfections and Severity in Hospitalized Children With Systematic Testing.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Di Chiara Costanza, Farrar Daniel S, Bettinger Julie A, Campigotto Aaron, Drouin Olivier, Embree Joanne, Halperin Scott A, Jadavji Taj, Kazmi Kescha, Papenburg Jesse, Purewal Rupeena, Sadarangani Manish, Sauvé Laura, Top Karina A, Kakkar Fatima, Morris Shaun K, for Members of the Canadian Immunization Monitoring Program, Active (IMPACT) COVID-19 Study
Аннотация
BACKGROUND: Co-circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with other respiratory viruses raised concerns that coinfections may increase pediatric coronavirus disease 2019 (COVID-19) severity, but evidence is limited by variable testing practices. We assessed the epidemiology and outcomes of SARS-CoV-2 respiratory viral coinfections in hospitalized children.
METHODS: We analyzed national surveillance data from the Canadian Immunization Monitoring Program, ACTive (IMPACT) COVID-19 study. Children aged <17 years hospitalized with confirmed COVID-19 during Delta and Omicron periods were included. Coinfection was defined as SARS-CoV-2 plus ≥1 additional respiratory virus. Primary analyses were restricted to centres with systematic multiplex polymerase chain reaction (PCR) testing of all admissions with acute respiratory illness (n = 5), while secondary analyses included all centres (n = 13). Associations with outcomes (respiratory support, ventilation, intensive care and severe COVID-19) were estimated using multivariable mixed-effects logistic regression and adjusted odds ratios (aORs).
RESULTS: Among 2831 hospitalized children, 938 were admitted at centers with systematic multiplex PCR testing, among whom 18.6% had ≥1 respiratory viral coinfection. Respiratory syncytial virus (39.7%) and enterovirus/rhinovirus (38.5%) coinfections were the most common. Coinfections were not associated with increased odds of severe COVID-19 in centers with systematic multiplex PCR testing (aOR 0.94; 95% confidence interval, 0.76-1.15). In secondary analyses including all centers irrespective of testing strategy, coinfections were associated with increased odds of severe COVID-19 (aOR 1.42; 95% confidence interval, 1.05-1.91).
CONCLUSIONS: In centers that systematically conducted multiplex PCR testing, SARS-CoV-2 respiratory viral coinfections were not associated with increased COVID-19 severity. Differences observed when including centers without systematic testing underscore the importance of considering testing strategies when evaluating the clinical impact of coinfections.
METHODS: We analyzed national surveillance data from the Canadian Immunization Monitoring Program, ACTive (IMPACT) COVID-19 study. Children aged <17 years hospitalized with confirmed COVID-19 during Delta and Omicron periods were included. Coinfection was defined as SARS-CoV-2 plus ≥1 additional respiratory virus. Primary analyses were restricted to centres with systematic multiplex polymerase chain reaction (PCR) testing of all admissions with acute respiratory illness (n = 5), while secondary analyses included all centres (n = 13). Associations with outcomes (respiratory support, ventilation, intensive care and severe COVID-19) were estimated using multivariable mixed-effects logistic regression and adjusted odds ratios (aORs).
RESULTS: Among 2831 hospitalized children, 938 were admitted at centers with systematic multiplex PCR testing, among whom 18.6% had ≥1 respiratory viral coinfection. Respiratory syncytial virus (39.7%) and enterovirus/rhinovirus (38.5%) coinfections were the most common. Coinfections were not associated with increased odds of severe COVID-19 in centers with systematic multiplex PCR testing (aOR 0.94; 95% confidence interval, 0.76-1.15). In secondary analyses including all centers irrespective of testing strategy, coinfections were associated with increased odds of severe COVID-19 (aOR 1.42; 95% confidence interval, 1.05-1.91).
CONCLUSIONS: In centers that systematically conducted multiplex PCR testing, SARS-CoV-2 respiratory viral coinfections were not associated with increased COVID-19 severity. Differences observed when including centers without systematic testing underscore the importance of considering testing strategies when evaluating the clinical impact of coinfections.